Seres Therapeutics Inc. (MCRB) Tumbled To A 2-Month Low On Study Results

Seres Therapeutics Inc. (MCRB) reported results from its Phase 1b study of SER-287 in patients with mild-to-moderate Ulcerative Colitis.

from RTT - Before the Bell http://ift.tt/2fNdX6B
via IFTTT